Research Peptides and GLP-1s: What They Are, and What Happened to Users

“Research peptides” are vials or powders sold online under labels like “for research purposes” or “not for human consumption,” containing GLP-1-type drugs such as semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide ^[1]. The FDA says those labels are false: the products are sold directly to consumers for human use, with dosing instructions attached, and are of unknown quality and may be harmful ^[1]. Buying them is not a legal route to any GLP-1 drug, and for retatrutide there is no lawful way for any pharmacy or seller to provide the drug at all ^[1][5][7].

The clearest picture of what actually happens to users comes from a preprint study reported August 26 and September 4, 2026, which pulled retatrutide mentions out of de-identified electronic health records at US academic medical centers ^[3][4]. It confirmed exposure in 652 patients, found that 71.2% of those with a documented supply route got the drug outside a clinical trial, and found that these gray-market users lost 7.2% of body weight at 6 to 12 months — under half the 15.5% recorded among trial participants over the same window — while still showing a rise in heart rate ^[3][4].

What are “research peptides” and how are they sold?

Online listings for “retatrutide peptide” are usually powders marketed as research chemicals, not the drug being tested in clinical trials ^[8]. The FDA has warned companies selling unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide that are falsely labeled “for research purposes” or “not for human consumption” — products that in practice reach consumers with dosing instructions ^[1]. The agency urges consumers not to buy them ^[1].

Demand has been driven by social media, peptide forums, and press coverage, with sellers and buyers using the shorthand “reta” ^[3][8]. Marketing often uses labels like GLP-1, GLP-2, GLP-3, or GIP therapy, and some sellers claim their injections are equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound ^[11]. Some gray-market products documented in clinical notes were co-formulated with other unapproved peptides such as cagrilintide, BPC-157, NAD+, and IGF-1 analogs ^[3].

Is it legal to buy retatrutide in the US?

No. Retatrutide is Eli Lilly’s investigational triple agonist (GIP, GLP-1, and glucagon), currently in Phase 3 trials, and no regulatory agency anywhere in the world has approved it ^[3][4][5]. Lilly has stated it cannot be sold to consumers ^[5]. Lilly plans to submit an application for FDA approval in the first quarter of 2027; approval timing beyond that is unknown ^[3][4].

The FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, active pharmaceutical ingredient distributors for selling retatrutide to compounders, and outsourcing facilities for repackaging it ^[1]. On September 9, 2025, the agency sent a warning letter to one seller stating that its compounded retatrutide products were unapproved new drugs and misbranded drugs in violation of sections 505(a) and 502(f)(1) of the Federal Food, Drug, and Cosmetic Act ^[7].

Does a “not for human consumption” label make the sale legal?

No. The FDA states these labels are false when the products are sold directly to consumers for human use with dosing instructions ^[1]. Lilly, which makes retatrutide and has a commercial interest in stopping the gray market, says sellers using “research-use only” claims are selling illegal drugs ^[5].

Can a compounding pharmacy legally make retatrutide?

No. The FDA has told state boards, in a March 31, 2025 letter from its Division of Compounding II to the National Association of Boards of Pharmacy, that retatrutide has no USP monograph, is not a component of any approved drug, and appears on neither the 503A nor the 503B bulk substances lists — so compounded retatrutide qualifies for the exemptions under neither section of federal law ^[4][7]. The same reasoning appears in the FDA’s September 9, 2025 warning letter ^[7]. The FDA has also stated that retatrutide and cagrilintide cannot be used in compounding under federal law ^[1].

What did the 652-patient study actually find?

Researchers at nference, a health data company, used large language models to extract retatrutide mentions from de-identified clinical notes at US academic medical centers, then had clinicians sort real use from mentions by patients who only considered or declined the drug ^[3][4]. Of 983 patients whose notes mentioned retatrutide, 652 (66.3%) had confirmed exposure and 531 (54%) had a documented supply route ^[3].

Of those 531, 378 (71.2%) obtained the product outside a clinical trial: 217 (57.4%) through online or telehealth vendors, 111 (29.4%) through compounding pharmacies, and 33 (8.7%) through wellness clinics or medical spas ^[4]. Use rose 1.8-fold per quarter from October 2023 through March 2026, reaching 228 new users in the first quarter of 2026 ^[3][4].

The researchers built matched cohorts: 89 trial participants, 243 direct-to-consumer users, 890 semaglutide users, and 890 tirzepatide users, balanced at about age 51, about 63% women, and BMI about 33 ^[3]. At 6 to 12 months, direct-to-consumer users lost a mean of 7.2% of body weight versus 15.5% among the trial cohort (P=0.004), and about the same as matched tirzepatide users at 7.7% ^[3][4].

The trial comparator here is not a published trial result. It is the record of patients whose notes identified them as enrolled in a retatrutide trial, read over the same window, and it includes an unknown number who received placebo ^[4].

What heart effects were seen?

Mean heart rate rose +2.5 beats per minute at three months among direct-to-consumer users (P=0.011) and +4.3 bpm among trial participants (P=0.028), while changing 0.0 bpm among matched semaglutide users and 0.1 bpm among matched tirzepatide users ^[3][4]. Pooling both retatrutide cohorts, new-onset tachycardia was 2.88 times more frequent than among matched tirzepatide users (95% CI 1.68-4.85) ^[4]. Pooled retatrutide users also showed higher rates of new-onset cardiovascular symptoms (RR 1.56) and neuropsychiatric symptoms (RR 1.95) versus the comparators ^[3].

Venky Soundararajan, founder and chief scientific officer of nference, said the pattern suggests at least some patients received a biologically active product capable of incretin-like cardiovascular effects, but without trial-level weight-loss efficacy ^[4].

What are the limits of that study?

It is a preprint and observational, so it cannot prove cause ^[3]. Follow-up was short and uneven — a median of about 3 months in the retatrutide arms versus about 6 months in the comparator arms ^[3]. The authors are nference employees, and the company sells the analysis software used; the study itself received no pharmaceutical company funding ^[3][4]. Priya Jaisinghani, an obesity specialist at NYU Langone Health who was not involved, said the study provides an important signal that patients are obtaining unapproved retatrutide through channels where product, dose, purity, and efficacy cannot be verified; she has consulted for Lilly and Novo Nordisk ^[3].

Why did people leave approved drugs for the gray market?

Most gray-market users had no record of a prior approved obesity drug, and among those who did, most had been on a Lilly medicine ^[4]. The reasons recorded for leaving an approved drug were that it was too expensive, not working well enough, or hard to tolerate ^[4]. In 67% of 260 direct-to-consumer cases, the patient — not the clinician — raised retatrutide first ^[4].

Because retatrutide has no national drug code, no pharmacy claim, and no prescription record, this use is invisible to standard drug safety monitoring ^[3][4]. Epic and Oracle Health’s Cerner, the major electronic health record platforms, have no structured field for recording gray-market use, so clinicians only learn about it when a patient volunteers it ^[4].

Who sells it, and what has enforcement looked like?

On August 12, 2026, Lilly filed six lawsuits against US sellers: Aesthetic Envy Cosmetic Centers (N.D. Cal.), Astra LLC d/b/a Astra Peptides (W.D. Tex.), Legendary Peptides (E.D. Tex.), Striker Pharmacy (S.D. Tex.), Texas Peptides (W.D. Tex.), and Lone Star Peptide (S.D. Tex.) ^[5]. The defendants include compounding pharmacies, medical spas, wellness clinics, and online sellers claiming “research-use only” products ^[5][6].

Lilly says it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement, and licensing boards, and has reported more than 14,000 websites, ads, posts, and listings in over 100 countries ^[2][5]. CBS News reported in June 2026 that dozens of professional clinics were advertising the drug ^[2]. A Lilly spokesperson told Medscape that patients have reported serious harms after taking black-market retatrutide purchased online, including hospitalizations ^[3]. Lilly is the manufacturer with a commercial interest in these claims, so its statements are its own ^[5].

What has been found in seized or tested product?

Analysis of seized counterfeits has found doses ranging from zero to overdose levels, and completely different active ingredients, including insulin ^[6]. Many products are thought to be made in non-sterile conditions and may be contaminated with microorganisms — a particular concern for an injectable ^[6]. Organized crime networks have reportedly begun manufacturing counterfeit retatrutide with fake brand names and bespoke packaging, often imported from China ^[6]. In October 2025, the UK’s MHRA seized 2,000 pen injectors purporting to contain retatrutide or tirzepatide, plus tens of thousands of empty pens, from a single site ^[6]. There have been reports of serious side effects, including liver failure, among people sourcing these products illicitly ^[6].

The FDA says illegally marketed semaglutide and tirzepatide may be counterfeit, may contain wrong or harmful ingredients, and may contain too little, too much, or no active ingredient at all ^[1].

How are research peptides different from compounded GLP-1s?

Compounded drugs are made under two legal pathways: section 503A covers drugs compounded by a licensed pharmacist in a state-licensed pharmacy or by a licensed physician, and 503B covers registered outsourcing facilities ^[7]. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before marketing ^[1]. The agency says compounded drugs should only be used when a patient’s medical need cannot be met by an FDA-approved drug, and that patients should obtain a prescription and fill it at a state-licensed pharmacy ^[1].

As of May 31, 2026, the FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide — counts the agency says are likely underreported ^[1]. Those counts cover compounded products, not research-labeled peptides specifically.

Research-labeled retatrutide fails both pathways: it has no USP monograph, is not a component of an approved drug, and is on neither bulks list, so there is no lawful compounding route for it at all ^[4][7].

What can go wrong with an unregulated injectable?

Beyond what seizures have shown, Drugs.com lists the specific failure modes: the vial may be counterfeit, mislabeled, substituted with a different substance, or nothing more than inert powder ^[8]. Without GMP manufacturing or FDA oversight, products may contain microbes, endotoxins, or particulates that can cause serious infections ^[8]. Approved GLP-1 injectables are stored between 2°C and 8°C (36°F to 46°F), and shipping conditions for online peptides are unknown ^[8]. The FDA has received complaints of compounded GLP-1s arriving warm or with inadequate ice packs ^[1]. Buyers who mix and inject powders themselves risk reconstitution errors, dosing mistakes, and overdose ^[8]. And with no medical screening, drug interactions, contraindications, and underlying conditions go unreviewed ^[8]. Without monitoring, nausea, dehydration, muscle loss, and nutrient deficiencies can go unnoticed ^[11].

What are the legal routes instead?

FDA-approved GLP-1 options for weight management include Saxenda (liraglutide, daily injection), Wegovy (semaglutide, weekly), and Zepbound (tirzepatide, weekly) ^[8]. The only authentic retatrutide is in Lilly-sponsored clinical trials ^[8]. Lilly has also opened an expanded access program for certain patients with severe refractory obesity — a regulated route that is distinct from the gray market ^[3]. Jaisinghani’s view was that patients deserve access to safe, evidence-based treatments ^[3].

What if you have already used one?

Clinicians quoted in the coverage advise asking patients directly about unapproved peptide use, and where use is disclosed, the researchers said heart rate warrants monitoring ^[3]. Patients are encouraged to report adverse events ^[3]. The FDA accepts reports through MedWatch online or by fax at 1-800-FDA-0178, and its CDER Division of Drug Information can be reached at 855-543-3784 ^[1]. Lilly’s Answers Center at 1-800-LillyRx takes reports of illegal products ^[5].

Sources

1. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
2. BioPharma Dive. Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide.
3. Medscape Medical News. Gray-market retatrutide: less weight loss, more CV effects. August 26, 2026.
4. Los Angeles Times. Gray-market retatrutide: what a 652-patient study found on weight loss.
5. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. August 12, 2026.
6. pharmaphorum. Lilly sues over ‘illegal sales’ of obesity drug retatrutide.
7. US Food and Drug Administration. Warning letter: GLP-1 Solution. September 9, 2025.
8. Drugs.com. What is ‘retatrutide peptide’ being sold online? April 29, 2026.
9. US Food and Drug Administration. Questions and answers about FDA’s initiative against contaminated weight loss products.
10. Nutrition Insight. Gray market peptides blur drug and supplement distinctions, raising health risks.
11. Southwest Family Physicians. Grey-market GLP-1s, peptides, and retatrutide: what to know before you inject.